Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Typhoon, Tractor4sale, Pendulum,Webster.Have a nice weekend. -Pier.
Is it? Was TSOI a share selling operation back on August 9, 2021? Or is it just something that is new this past year? I find it hard to believe that anyone could love the DD of a share selling operation of a company that has been non profitable for well over the last decade! Go figure…
It’s just a share selling operation period
I hear ya. Mark Cuban had a good quote the other day it’s better to have 50% of a watermelon then 100% of a grape.
In my opinion if we would’ve partnered with a big Pharma everything would be going I believe faster they know more short cuts they have a finding they have it all. It was able to stew proceed with a bunch of our other patents in the Cetra.
But that’s not going to work our CEO loves the message boards and see who’s pissing them off. There might be but I don’t I haven’t never seen any other CEOs take time out for a message board.
Hopefully this coming week we will hear from the FDA on incorporating COPD into the phase 3 with Covid on the Jedi cell.
In my opinion I like the science of this company extremely well and think it can go far but we have to do something different what’s being done now it’s just not working.
We didn't expect incompetence.
Just think that even though there wasn’t a big partner lined up after Phase 2, that didn’t stop investors from becoming TSOI shareholders! At the same time, knowing TSOI didn’t have a big pharmaceutical partner lined up after Phase 2, any current shareholders at that time that didn’t like that could have walked away when the share price was much higher! No big partnership and the Phase 3 press release last August took the share price to .13! What does that say about any disgruntled shareholders complaining about no big partnerships being lined up after Phase 2 that still decided to hold? Oh well! Maybe next time!
What are you talking about, phase 2 was a human clinical trial!
Merck has offered 40 Billion to acquire an oncology company called Seagen for a cancer drug. Point being pharma has money, where are the partnerships? Didn't TSOI used to have this code "big pharaoh" for big pharma? Well.....?
If TSOI doesn't want to be acquired because they believe to be worth a trillion or so (..... ok back from laughing), are partnerships out of the question too?
This is what I meant by string along!
So yeah, excuse me if I get a little disheartened if all I see is a shed next to a forest and stock down 90% the past year when other companies are making progress, all while increasing shareholder value. What a shocking concept!
Lots of deals are being made this year. What is the largest one? Pfizer is going to pay $5.4 Billion to acquire Global Blood Therapeutics for sickle cell disease treatment still part of phase 2/3 trials among other IP. And yet we have not even a partnership for a treatment that showed great efficacy compared to bone marrow MSCs? What gives??
To give an example what "real" bio companies do, Capricor, as mentioned earlier, was wise enough to obtain millions in state funding as non- dilutive grants, then partnered with Japanese pharma for an upfront payment and milestone payments that will total close to a billion for one of their IP to treat muscular dystrophy. Capricor will be manufacturing it (think of us manufacturing the cells) and Japan pharma will be commercializing it in the US and Japan. This is how companies treat people and make money, the latter part which for some reason TSOI doesn't seem to understand how to accomplish.
Patents are not helpful to shareholders if they are not taken to market, commercialized, licensed or sold. For ARDS, we should have had a big partner signed with us after phase 2 showed efficacy. Certainly during phase 3. TSOI needs a partnership with big bucks, knowledge, experience, and manpower to take it to the next level. I don't mind being patient, but seeing "negative" and "abnormal" progress contrary to what "traditional" and "normal" bio companies do has obliterated any confidence I had in TSOI's management.
Of course a partnership will want something in return, but Tim doesn't want to give up any control. I still cannot fathom how he thinks his company is worth trillions surpassing big pharma! Utter nonsense.
Or there are lots of potential TSOI investors who believe there is no sense of urgency to buy now because the phase 3 trials results won’t be out till probably the middle of 2023! There are better short term trades to be a part of in the meantime! Just play the TSOI game because that’s what longs do…
Yeah I mean volume and share price speak to the lack of a real leader here. People do not trust Tim Dixon. It’s that simple. If they did they would line up to get shares.
Simply not happening. But I’m sure he will continue to blame everyone but his damn self. I mean that’s what penny CEOs do right?
Have a good weekend man. Nothing to see here. Cheers
Ever wonder why there seems to be an endless supply of TSOI shares available for sale & @ these low pps levels. Perhaps the below helps to possibly clarify.
It was a ploy to keep the pps from completely tanking? But it tanked regardless! Just like it did in February! Why is that?
But but dilution subsidiaries!
I mean he will lie to you though as he has so done in the past many a time with oh yeah quadramune coming in Costco…… ummm nope.
Or weeks later “we’re gonna be in 600 stores in a few weeks” half a year later ummmmmm nope. It’s just like upon lie and it’s all documented on the forum
The biggest of course which I believe is pure fraud is his press release where Tim decided to lie to investors in the midst of a pandemic trying so hard to come across as a saint with lying about rushing to file for EUA when he stone cold KNEW he could not file. It was a ploy I believe to keep the pps from completely tanking. It also kept investors like myself invested believing EUA filing was happening right away.
He then kept the lie rolling for the next 6 months stating EUA was happening. He would attack any investor asking about it as well. What people need to see is this sort of ploy to deceive investors is illegal.
Nice ask slap @ 10:24:33 680k @ 0102
bids still in place GTC
In my opinion Tim should’ve took your advice sell at $.13 and not a penny in under. Now all he’s doing is hurting everyone.
I know you don’t agree but in my opinion we need an experienced CEO and a Board of Directors and legit 7 to 9 Board of Directors that can run this company right.
Last I heard he was going to spin off some companies what happened to that course we spin off some before and with all that good.
I am personally concerned about this company going belly up you just can’t keep authorize and more shares that sell. Pretty soon you run out of investors.
I’ve asked you this before but you didn’t answer or you didn’t want to answer but why gift item 55 million shares what good did that do us at the point that we are in now with no money to do anything except go to Idaho and tear down a couple of buildings big deal.
I’m also hearing there’s no picnic and 23 which I knew from the get-go it wasn’t gonna happen anyway now I think many are waking up and smell in the coffee.
Mmmm sorry but penny stocks like TSOI don’t hold gains! That’s why investors shouldn’t love the DD until closer to when trials are completed! When popular stocks that trade on major stock exchanges are down significantly this year, it’s easy to understand why a time consuming penny biotech stock is down as well…
Mmmmm sorry he’s a respected penny investor and sees right through the bs going on here due to the incompetency of one Tim Dixon. So praise him when he’s rooting and slaughter him when he figures out the sham?
AYE, YOU WERE LUCKY! ALLS WE GOT WAS A ROLLED UP NEWSPAPER --IN THE MIDDLE OF THE ROAD---- AND---
by TimGDixon » Sun Sep 11, 2022 1:01 pm
to all this...
9,803,176 B2
Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.
08-12-2022 Treatment of Chronic Obstructive Pulmonary Disease by Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof
07-29-2022 Gene Modified iPSC Derived Cellular Compositions for Regeneration and Immune Modulation
05-12-2022 Inhibition and Reversion of Chronic Obstructive Pulmonary Disease (COPD) by Endothelial Cell Regeneration
03-07-2022 Treatment of Trauma Associated Cognitive Dysfunction Using Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof
11-01-2021 Induction of Concurrent Pulmonary Immune Modulation and Regeneration by Protein Mediated Conjugation of Immune Regulatory Cells with Endogenous Progenitor Cells
10-11-2021 Umbilical Cord Derived Regenerative and Immune Modulatory Stem Cell Populations
10-04-2021 Reduction of Neutrophil Extracellular Trap formation by Mesenchymal Stem Cells and their Exosomes
09-22-2021 Stimulation of Mesenchymal Stem Cell Therapeutic Activities by T Regulatory Cells
08-23-2021 Umbilical Cord Mesenchymal Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease and Lung Degeneration
08-18-2021 Enhancement of Umbilical Cord Mesenchymal Stem Cell Therapeutic Activity by Stimulators of T Regulatory Cells and/or Cells Expressing CD73
08-11-2021 Induction of Neurogenesis using Umbilical Cord Derived Mesenchymal Stem Cells and Derivatives Thereof
07-06-2021 Treatment of Parkinson’s Disease by Immune Modulation and Regenerative Means
05-21-2021 Lithium as a Monotherapy and/or Stem Cell Adjuvant Therapy for Pulmonary Fibrosis
10-27-2020 Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia
That’s the truth!
Buys 1,677,395 Sells 3,480,008 ? 46,944
& yes ALL the investing public knows the rhetorical BS about every trade is a buy
Once in their heads
The share price started to plummet from .13 within days of the August Phase 3 and EUA press release and the stock was back at .05 by October 1, 2021! That tells me most investors knew how long it would take to initiate the Phase 3 and get the results! Penny stocks don’t hold gains this was another perfect example of the February 2021 sell off from .17 down to .03 in 4 months! Penny stock traders reference charts to plan their trading strategy…
You’re talking about Tim selling 10 million shares out of his 280 million shares and a penny so why didn’t Cam take your advice as you gave him the rest of us that this is a penny stock and when it hit $.13 why didn’t we sell. He lost a lot of money they’re not taking advantage of the $.13 that’s what you’ve told us all along that we should’ve sold.
The reason that most of us didn’t sell at $.13 was we bought in August a year ago on his PR that the phase 3 in the UA was top priority and blah blah blah blah.
In my opinion it’s pathetic how this company is being ran it could be such a great company it has many many many profit centers that’s coming down the line but sometimes you have to give up one or two to sell them or take a partnership or whatever to be able to operate. You have to give-and-take problem is Tim don’t give he wants at all he’s the big man with the big ego at strictly my opinion but that’s the truth so therefore we are setting at a penny and less some at sometimes
I told other investors and from my area I knew the enrollment has not started when he can’t post have it posted on that clinical trial.gov it ain’t happening. That you all keep believing that crap and then you’d be little or jump on the ones that knew it wasn’t happening what a farce.
Nice to see the opening Bid above yesterday's close (currently) & w/ a nice ask slap
GLTA
Hello TSOI people, I haven't been here for over a year and I don't know much what is going on. Was there any reverse split or any major happenings for this ticker? Why it went down so much? I appreciate your input.
I'm all in on THAT Yogi! Seen it many times ,, What a difference a day makes..milly BillY TRILLY TSOI
It ain’t over until it’s over. One thing Ive learned about news is that nobody ever knows when it’s coming.
Milly Billy Trilly
it might get a tad darker Merica aint out of the woods yet GOOOOOOO TSOI
It’s always darkest before the blessings come my friend.
Ameesge to To Tim Dixon:
Karma's not a liar
She keeps receipts
I think you missed her point...lol
G means GIFT not a sale...
the filing is even highlighted in RED!!! good gawd vhen momma says a sucker is born every minute she no joke.
D means DISPOSED! you have another definition ?
nope, the codes are important
tim Dixon sold 10.5 million shares on September 8th
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/stock-news/89022882/statement-of-changes-in-beneficial-ownership-4
TSOI Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
\https://www.otcmarkets.com/stock/TSOI/profile
TSOI y PAUL btw Wonder if any of the investing public has any/all trade data relating to PAUL (institutional) era
Insiders no Form 4s filed or needed / Noteholders cashing out (as is their right) from Dixon's selling of (discounted?) paper to survive, well now sadly that's another story entirely
https://www.sec.gov/comments/s7-24-20/s72420-228879.htm
Any really wonder what’s happening to the pps. Get Real just look @ O/S y DTC. ONLY 1 person I know of??? Who can originate/sign off on those notes.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On January 4, 2022, we issued 1,034,482 shares of common stock for $30,000 of accrued salaries.
On January 14, 2022, we issued 4,158,759 shares of common stock for the complete conversion of $56,975 for convertible note dated July 12, 2021.
On February 4, 2022, we issued 4,778,689 shares of common stock for the complete conversion of $58,300 for convertible note dated August 2, 2021.
On February 14, 2022, we issued 24,500,000 shares of common stock, valued at $0.01 per share, for an investment in the Company’s Private Placement.
On February 24, 2022, we issued 10,000,000 shares of common stock, valued at $0.01 per share, for an investment in the Company’s Private Placement.
On February 23, 2022, we issued 149,402,390 shares of common stock, valued at $0.0208 per share, for a license.
On March 31, 2022, we issued 10,000,000 shares of common stock, valued at $0.01 per share, for an investment in the Company’s Private Placement.
On April 4, 2022,we issued 6,786,585 shares of common stock for the complete conversion of $83,475 for convertible note dated October 1. 2021.
On April 5, 2022, we issued 9,000,000 shares of common stock, valued at $0.0251 per share, for consulting services.
On May 2, 2022, we issued 7,000,000 shares of common stock, valued at $0.026 per share, for consulting services.
On May 2, 2022, we issued 3,571,994 shares of common stock for the complete conversion of $56,438 for convertible note dated November 2, 2021.
On May 3, 2022, we issued 2,000,000 shares of common stock, valued at $0.0254 per share, for consulting services.
On May 4, 2022, we issued 2,000,000 shares of common stock, valued at $0.0259 per share, for consulting services.
On May 24, 2022, we issued 2,000,000 shares of common stock, valued at $0.02261 per share, for consulting services.
On June 16, 2022, we issued 2.919.708 shares of common stock for the partial conversion of $40,000 for convertible note dated December 15, 2021.
On June 17, we issued 1,951,993 shares of common stock for the complete conversion of $26,938 for convertible note dated December 15, 2021.
Item 1. Legal Proceedings
From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.
However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.
https://www.otcmarkets.com/filing/html?id=16030841&guid=o1w-kKH-nwOCJth
Does a Pink Sheet company even have to file a Form 4? I do not believe so. If it has been done in the past, it was voluntary. Pink sheets do not have the same filing requirements of the higher tier OTC exchanges.
Followers
|
525
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
65550
|
Created
|
10/04/08
|
Type
|
Free
|
Moderators BigBadWolf johnnytrader33 JMC$ Yooperman Hogwarts |
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.
"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."
"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."
"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."
"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."
1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |